Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

EBOS Group's , major shareholder Sybos is selling NZ$949 million ($566.74 million) worth of shares in the New Zealand-based medical equipment manufacturer, according to a term sheet by Reuters.

Outset Ventures, the Auckland-based venture firm and incubator that spun out deep tech unicorns like Rocket Lab and LanzaTech ...

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

Swiss drugmaker Roche said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

Roche and Tandem Diabetes settle patent disputes over insulin devices with a $36M agreement and 10-year cross-licenses. Read ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Forget the needle.